Vitamin D threshold to prevent aromatase inhibitor-related bone loss: The B-ABLE prospective cohort study

Breast Cancer Research and Treatment

Volumn 133, Issue 3, 2012, Pages 1159-1167

  Prieto Alhambra, Daniel ^a,b,c,d,e   Servitja, Sonia ^d,e,f   Javaid, M Kassim ^b   Garrigós, Laia ^e,f   Arden, Nigel K ^b   Cooper, Cyrus ^b,g   Albanell, Joan ^d,e,f   Tusquets, Ignasi ^d,e,f   Diez Perez, Adolfo ^a,d,e,h   Nogues, Xavier ^a,d,e,h  

^a Barcelona Biomedical Research Park   (Spain)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Research Institute University Primary Care IDIAP Jordi Gol   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Oncology Department   (Spain)

^g SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^h Parc de Salut Mar   (Spain)

Author keywords

Aromatase inhibitors; Breast neoplasms; Epidemiology; Osteoporosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CALCIUM; COLECALCIFEROL; EXEMESTANE; LETROZOLE; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D;

25 HYDROXYCOLECALCIFEROL BLOOD LEVEL; ADULT; ARTICLE; BONE DENSITY; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

AGED; AROMATASE INHIBITORS; BONE DENSITY; BONE RESORPTION; COHORT STUDIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; VITAMIN D;

EID: 84863724098     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2013-9     Document Type: Article

References (36)

1. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 369(9561):559-570
2. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784-3796
3. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. doi:10.1056/NEJMoa1103507
4. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486-492
5. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453):60-62
6. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455-462
7. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45-53
8. Crivellari D, Sun Z, Coates AS, Price KN, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26(12):1972-1979
9. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26(7):1051-1057
10. Doughty JC (2008) A review of the big results: the breast international group 1-98 trial analyses. Breast 17(Suppl 1):S9-S14
11. Nogues X, Servitja S, Pena MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I (2010) Vitamin D deficiency and bone mineral density in postmeno-pausal women receiving aromatase inhibitors for early breast cancer. Maturitas 66:291-297
12. Cauley JA, Parimi N, Ensrud KE, Bauer DC, Cawthon PM, Cummings SR, Hoffman AR, Shikany JM, Barrett-Connor E, Orwoll E (2010) Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res 25(3):545-553. doi:10.1359/jbmr.090826
13. Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, Lee JS, Jackson RD, Robbins JA, Wu C, Stanczyk FZ, LeBoff MS, Wactawski-Wende J, Sarto G, Ockene J, Cummings SR (2008) Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 149(4):242-250
14. 3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326(7387):469. doi: 10.1136/bmj.326.7387.469
15. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C (2007) Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 46(12):1852-1857
16. 3 and calcium for secondary prevention of low-trauma fractures in elderly people (randomised evaluation of calcium or vitamin D, record): a randomised placebo-controlled trial. Lancet 365(9471):1621-1628
17. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339:b3692
18. Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-Garcia M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat. doi:10.1007/s10549-010-1075-9
19. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA (2011) The 2011 report on dietary reference intakes for calcium and vitamin d from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 96(1):53-58
20. Servitja S, Nogues X, Prieto-Alhambra D, Martinez-Garcia M, Garrigós L, Pena MJ, de Ramon M, Diez-Perez A, Albanell J, Tusquets I (2012) Bone health in a prospective cohort of post-menopausal women receiving aromatase inhibitors for early breast cancer. Breast 21(1):95-101
21. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Som-erfield MR (2004) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report. J Clin Oncol 23(3):619-629
22. Orozco Lopez P, Zwart Salmeron M, Vilert Garrofa E, Olmos Dominguez C (2004) Prediction of the total calcium intake from consumption of milk products in Spain adult population. INDI-CAD study 2001. Aten Primaria 33(5):237-243.
23. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL (2009) Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 117(3):603-609. doi: 10.1007/s10549-009-0332-2
24. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlbock M, Jakesz R (2008) Adjuvant endocrine therapy plus zoledronic acid in pre-menopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840-849
25. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol 8(2):119-127
26. Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H Management of anas-trozole-induced bone loss in breast cancer patients with oral risedronate: results from the arbi prospective clinical trial. Breast Cancer Res 12(2):R24.
27. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmeno-pausal women with early breast cancer receiving adjuvant le-trozole: ZO-FAST study results. Cancer 112(5):1001-1010. doi: 10.1002/cncr.23259
28. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffels-taedt JP, Clack G, Barlow D, Makris A, Eastell R (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the sabre trial. J Clin Oncol 28(6):967-975
29. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, Kim D (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-meta-static breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118(1):81-87. doi:10.1007/s10549-009- 0352-y
30. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 34(Suppl 1):S3-S18
31. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR (2011) Calcium supplements with or without vitamin d and risk of cardiovascular events: reanalysis of the women's health initiative limited access dataset and meta-analysis. BMJ 342:d2040
32. Rastelli AL, Taylor ME, Gao F, Armamento-Villarreal R, Ja-malabadi-Majidi S, Napoli N, Ellis MJ (2009) Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled randomized trial. Breast Cancer Res Treat 129:107-116. doi:10.1007/s10549-011- 1644-6
33. Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B, Orav JE, Li R, Spiegelman D, Dietrich T, Willett WC (2009) Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. J Bone Miner Res 24(5):935-942. doi:10.1359/jbmr.081242
34. Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J (2009) Prevention of nonvertebral fractures with oral vitamin d and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 169(6):551-561
35. Nieves JW, Barrett-Connor E, Siris ES, Zion M, Barlas S, Chen YT (2008) Calcium and vitamin d intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the national osteoporosis risk assessment (NORA) study. Osteoporos Int 19(5):673-679. doi:10.1007/s00198-007- 0501-2
36. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303(18):1815-1822